Cerus Corporation (CERS) Analysts See $-0.12 EPS

April 20, 2018 - By Clifton Ray

Investors sentiment increased to 1.45 in 2017 Q4. Its up 0.13, from 1.32 in 2017Q3. It is positive, as 6 investors sold Cerus Corporation shares while 25 reduced holdings. 14 funds opened positions while 31 raised stakes. 58.96 million shares or 2.97% more from 57.26 million shares in 2017Q3 were reported.
Royal Bank & Trust Of Canada invested in 5,247 shares. Northern Tru owns 1.32 million shares. State Board Of Administration Of Florida Retirement Sys invested in 0% or 36,846 shares. California State Teachers Retirement System owns 178,503 shares or 0% of their US portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) owns 0% invested in Cerus Corporation (NASDAQ:CERS) for 3,402 shares. Jpmorgan Chase & Co has invested 0% of its portfolio in Cerus Corporation (NASDAQ:CERS). Manufacturers Life Ins Company The holds 0% or 91,141 shares in its portfolio. 815,924 are held by Raymond James And Assocs. Envestnet Asset Inc holds 0% of its portfolio in Cerus Corporation (NASDAQ:CERS) for 5,377 shares. New York State Common Retirement Fund invested 0% in Cerus Corporation (NASDAQ:CERS). Primecap Co Ca owns 7.80M shares or 0.02% of their US portfolio. Susquehanna Gru Limited Liability Partnership holds 154,897 shares or 0% of its portfolio. Millrace Asset Gru reported 1.28% of its portfolio in Cerus Corporation (NASDAQ:CERS). Zeke Capital Advsr Ltd Liability Corp reported 0.01% of its portfolio in Cerus Corporation (NASDAQ:CERS). Bb&T Securities Ltd Liability Corp owns 41,107 shares for 0% of their portfolio.

Since March 10, 2018, it had 1 buying transaction, and 5 sales for $597,723 activity. Menard Chrystal also sold $22,793 worth of Cerus Corporation (NASDAQ:CERS) on Saturday, March 10. CORASH LAURENCE M also bought $773,199 worth of Cerus Corporation (NASDAQ:CERS) shares. Greenman William Mariner had sold 17,766 shares worth $87,795 on Saturday, March 10. 4,737 shares were sold by Green Kevin Dennis, worth $23,409 on Saturday, March 10. Benjamin Richard J sold $18,328 worth of Cerus Corporation (NASDAQ:CERS) on Saturday, March 10.

Analysts expect Cerus Corporation (NASDAQ:CERS) to report $-0.12 EPS on May, 2.They anticipate $0.06 EPS change or 33.33 % from last quarter’s $-0.18 EPS. After having $-0.10 EPS previously, Cerus Corporation’s analysts see 20.00 % EPS growth. The stock decreased 3.00% or $0.17 during the last trading session, reaching $5.49. About 588,668 shares traded. Cerus Corporation (NASDAQ:CERS) has risen 26.07% since April 20, 2017 and is uptrending. It has outperformed by 14.52% the S&P500.

Cerus Corporation (NASDAQ:CERS) Ratings Coverage

Among 2 analysts covering Cerus Corp (NASDAQ:CERS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cerus Corp had 5 analyst reports since October 30, 2017 according to SRatingsIntel. Cantor Fitzgerald maintained it with “Buy” rating and $5.0 target in Monday, January 8 report. The stock of Cerus Corporation (NASDAQ:CERS) has “Buy” rating given on Thursday, March 8 by Cantor Fitzgerald. On Wednesday, January 24 the stock rating was maintained by Robert W. Baird with “Buy”. Robert W. Baird maintained Cerus Corporation (NASDAQ:CERS) on Thursday, November 30 with “Buy” rating. The stock of Cerus Corporation (NASDAQ:CERS) earned “Buy” rating by Robert W. Baird on Monday, October 30.

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company has market cap of $711.49 million. The Company’s INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. It currently has negative earnings. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion.

Cerus Corporation (NASDAQ:CERS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: